Prognostic factor of local recurrent breast cancer following therapy in Padang-Indonesia

29^th Euro-Global Summit on Cancer Therapy & Radiation Oncology

July 23-25, 2018 | Rome, Italy

Daan Khambri, Wirsma Arif Harahap, Rony Rustam and Azamris

Andalas University, Indonesia

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

The objective of this study was to obtain the effectiveness of therapy in breast cancer patients with local recurrence. This study is a retrospective cohort study based on survival analysis in 83 patients with locally recurrent breast cancer at Dr. M. Djamil General Hospital in three trial groups: first group (get adjuvant chemotherapy and radiation therapy); the second group (get adjuvant chemotherapy but not radiation therapy) and the third group (not get adjuvant chemotherapy and radiation therapy). A total of 83 subjects were analyzed with median age of 48 years (27�73 years) at diagnosis. The percentage of first, second and third groups were 21.7%; 66.3% and 12%. This study shows that the survival rate of 10 years in the first, second and third groups were 93.17 months; 92.89 months and 63.60 months (p = 0.882; mean = 93.29 months). The prognostic factors affecting the survival of the subjects among the three trial groups were target therapy (HR=0.031; 95% CI 0.060�0.877), it means that target therapy is a protective factor in prognosis. Patients who get targeted therapy in addition to standard therapy had a better prognosis than those who did not get targeted therapy. This study shows the survival of the test group with complete adjuvant chemotherapy, radiotherapy and therapy (surgery, target therapy) is better than those who did not get complete therapy.
Recent Publications:
1. Wirsma A H and Daan K (2018) Outcomes of breast cancer treatment in West Sumatera�Indonesia. EJC 92(S3):S27.
2. Daan K and Wirsma A H (2017) Survival outcomes for Indonesian women with locally advanced triple-negative breast cancer. The Breast 32(1):S66.
3. Daan K and Wirsma A H (2017) Five years overall survival of locally advanced triple-negative breast cancer in West Sumatera, Indonesia. The Breast 36(1):S65.
4. Wirsma A H and Daan K (2017) Locally advanced breast cancer in Indonesia: prognostic and result of treatment. The Breast 36(1):S65.
5. Wirsma A H, Daan K, Ramadhan, Samuel J H and Ricvan D N (2017) Outcomes of trastuzumab therapy for 6 and 12 months in Indonesian National Health Insurance System Clients with operable HER2-positive breast cancer. APJCP 18(4):1151�1156.

Biography :

Daan Khambri graduated as General Practitioner from the Medical Faculty of Andalas University, Padang–West Sumatera. In 2003, he completed his General Surgery at the same faculty. He is interested continuing as an Oncological Surgeon and has a Combined Degree in Master of Health from the Medical Faculty of the Padjadjaran University, Bandung-West Java in 2007. In 2015, he completed a Post-graduate Doctoral Program at the Medical Faculty of Andalas University, Padang-West Sumatera. He is currently working as a Surgical Oncologist at Dr. M. Djamil General Hospital and active as a Lecturer at the Medical Faculty of Andalas University, Padang-West Sumatera.

E-mail: daan_khambri@yahoo.com